Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767695 | 1.00 | IL6ST (0.52) | IL6STHPGDDRD2DRD4STAT3 | |
| SCHEMBL18174202 | 0.88 | IL6ST (0.45) | IL6STDRD2DRD4STAT3PIK3CD | |
| SCHEMBL18174212 | 0.88 | IL6ST (0.45) | IL6STDRD2DRD4STAT3PIK3CD | |
| SCHEMBL18174204 | 0.88 | IL6ST (0.45) | IL6STDRD2DRD4STAT3PIK3CD | |
| SCHEMBL19183081 | 0.87 | IL6ST (0.52) | IL6STSTAT3PIK3CDIDH1ALDH1A1 | |
| SCHEMBL8225610 | 0.87 | IL6ST (0.52) | IL6STHPGDSTAT3PIK3CDIDH1 | |
| SCHEMBL4775861 | 0.87 | IL6ST (0.52) | IL6STSTAT3PIK3CDIDH1ALDH1A1 | |
| SCHEMBL4767686 | 0.87 | IL6ST (0.52) | IL6STSTAT3PIK3CDIDH1ALDH1A1 | |
| SCHEMBL9970272 | 0.87 | IL6ST (0.66) | IL6STHPGDSTAT3PIK3CDIDH1 | |
| SCHEMBL14523671 | 0.87 | IL6ST (0.66) | IL6STHPGDSTAT3PIK3CDIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590326-A4 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | EP | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | IL6ST 1991/4885HPGD 2533/4885DRD2 74/4885 |
| US-20060217418-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | IL6ST 1991/4885HPGD 2533/4885DRD2 74/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | IL6ST 1991/4885HPGD 2533/4885DRD2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.